文档介绍：TheallogeneictransplanthastheadvantageovertheautologoustransplantThegraftdoesnotcontaintumorcellsandthepotentialforagraftversusmyeloma(GvM)effectBonemarrowtransplantationinthreepatientswithmultiplemyelomaGahrtonG,RingdénO,LönnqvistB,LindquistR,;219(5):523--identicalsiblingdonorsOneofthepatients,withIgAkappamyeloma,refractorytoalkeran-herapy,iswellandstillwithoutsignofdisease26monthsposttransplantationAsecondpatientwithBence-Joneskappamyelomaiswell,andskeletalpainandBence--;219(5):523-7ConclusionBonemarrowtransplantationmaybeindicatedinaselectivegroupofpatientswithmultiplemyelomaActaMedScand1986;219(5):523-icmatchedsiblingdonortransplantsforMM344wereperformedduringtheperiod1983-93(allwithBM)[group1]356during1994-98(223withBMgroup2and133withPBgroup3)themedianageattransplantationofpatientsingroup1was43years(range21-62)Ingroup2,44years(range18_57)andingroup3,46years(range25_60)TBI+monlyusedingroup1(37%)and2(39%)thaningroup3(27%)Melphalancontainingregimestendedtobemorelyusedingroup3MelphalanorBusulphan+CYrarelyConditiongregimeEngraftment